SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations.

The beneficial effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown recently in numerous randomized controlled trials (RCT) and systematic reviews. According to KDIGO guidelines, SGLT2i currently represent a first choice for diabetic patients with chronic kidney disease (CKD). In addition, a recent meta-analysis of 13 large led by the 'SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium' (SMART-C) provided solid evidence of SGLT2i beneficial effects in CKD or in patients with heart failure, with and without diabetes.

[Non-steroidal anti-inflammatory drugs : clarification for the practitioner].

NSAID represent a widely used therapeutic class, but their side- effects profile can significantly limit their use. Introduction of selective cyclooxygenase-2 inhibitor has provided an alternative to non-selective NSAIDs, with a better digestive tolerance for similar efficiency. Nevertheless, introduction of these molecules has been associated with emergence of major cardiovascular events, motivating further studies on their safety profile.